NeoCore Technology Co., Ltd. (TPEX:4131)
33.60
-0.30 (-0.88%)
At close: May 29, 2026
NeoCore Technology Revenue
NeoCore Technology had revenue of 60.47M TWD in the quarter ending March 31, 2026, a decrease of -13.09%. This brings the company's revenue in the last twelve months to 235.54M, up 104.18% year-over-year. In the year 2025, NeoCore Technology had annual revenue of 244.66M with 297.52% growth.
Revenue (ttm)
235.54M
Revenue Growth
+104.18%
P/S Ratio
5.68
Revenue / Employee
5.35M
Employees
44
Market Cap
1.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 244.66M | 183.11M | 297.52% |
| Dec 31, 2024 | 61.55M | -3.18M | -4.92% |
| Dec 31, 2023 | 64.73M | -24.24M | -27.24% |
| Dec 31, 2022 | 88.97M | 42.00K | 0.05% |
| Dec 31, 2021 | 88.93M | -4.42M | -4.73% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Level Biotechnology | 718.58M |
| Meribank Biotech | 471.76M |
| GenMont Biotech Incorporation | 390.95M |
| Abnova (Taiwan) | 348.71M |
| Lukas Biomedical | 179.49M |
| Enimmune | 48.19M |
| Great Novel Therapeutics Biotech & Medicals | 1.21M |